Meeting Urgent Needs in Surveillance and Diagnostics. Zika

监控和诊断方面的迫切需求。寨卡病毒 火鸟生物分子科学有限责任公司 佛罗里达大学佛罗里达医学昆虫学实验室 史蒂文·A·本纳 巴里·W·阿尔托 摘要 寨卡病毒对美国公民和世界公民的潜在危害不需要 讨论。我们仍在了解该病毒的分布和对人类发育的影响。 子宫，以及它在患者唾液、性液和尿液中的分布。有几十个案子在 撰写本文时的美国，大部分是在海外获得的，公众的校外研究计划 卫生机构被要求寻求更好的公共卫生监测技术，并立即 寨卡病毒的人体诊断工具。例如，在巴西，迫切需要的是一项测试，以 在公共诊所区分登革热、基孔肯雅热和寨卡病毒；目前，这种区分是 根据询问患者的出现时间提出了各种 症状。这里提出的工作将为寨卡病毒提供这些技术和工具。 然而，这项工作将提供更多。今天，NIAID、CDC和其他公共卫生单位 负责管理传染病暴发从一种疾病转移到另一种疾病，每一个新的 疫情和新闻周期。这充其量是低效的。在紧急情况下的高效公共卫生服务- ING疾病需要一个强大且可重现的技术平台，该平台足够灵活，以确保- VEY对于任何新出现的传染病都没有危机。这里提出的工作提供了这样一个平台 作为其调查寨卡病毒并根据试剂将其与其他虫媒病毒区分开来的能力的一部分 来自合成生物学领域的创新，包括人工扩大的遗传信息-- 信息系统(宙斯盾)、自回避分子识别系统(SAMRS)、双核苷酸、 音译和基于进化的虫媒病毒序列分析，在Flor- 国际开发署医学昆虫学实验室(FMEL)，该实验室有活的实验室感染寨卡病毒、登革热和 基孔肯亚和火鸟，合成生物学和诊断技术的系列创新者。 这个R21项目将首先将寨卡病毒添加到已经建立的试剂盒中，该试剂盒可以检测22种其他常见的虫媒病毒 13我们将对扩展的套件进行基准测试，将其交付给FMEL中的Beta测试员，在FMEL中 读数是使用Luminex仪器完成的。这种独立的测试保证了科学的严谨性，并将 在12个月前完成。在第二年，我们将寻求一个更简单的系统，专注于特定地理位置的多元化 目标集，添加biversals来管理RNA病毒的序列进化，在10x目标中取代Luminex 通过基于4x4微阵列的读出进行分析，并尽可能地走向10倍多路系统 这可以在野外分析大约10只蚊子。为此，我们将实现以下具体目标： 该项目的成果将包括新的寨卡病毒科学，以及允许公共卫生服务的试剂盒 享受这些试剂创新在控制寨卡病毒爆发方面的优势，就像这些优势一样 现在在许多产品中都可以使用，包括FDA批准的用于人类诊断的产品。

Urgent Needs in Surveillance and Diagnostics. Zika Firebird Biomolecular Sciences LLC Florida Medical Entomology Laboratory, the University of Florida Steven A. Benner Barry W. Alto ABSTRACT The potential hazards of the Zika virus to both American citizenry and citizens of the world need no discussion. We are still learning the distribution and impact of the virus on human development in utero, as well as its distribution in patient saliva, sexual fluids, and urine. With several dozen cases in the US at the time of this writing, most obtained overseas, the extramural research programs of public health agencies are being asked to seek better public health surveillance technologies and immediate human diagnostics tools for Zika. For example, in Brazil, the immediate need is a test that to distinguish between dengue, chikungunya, and Zika in public clinics; at this time, this distinction is made based on interrogation of patients with respect to the timing of the appearance of various symptoms. The work proposed here will deliver those technologies and tools for Zika. However, this work will provide more. Today, the NIAID, CDC, and other public health units responsible for managing infectious disease outbreaks move from disease to disease, with each new outbreak and news cycle. This is inefficient, at best. Efficient public health services in an age of emerg- ing diseases need a robust and reproducible technology platform that is sufficiently flexible to sur- vey for any emerging infectious diseases without crisis. The work proposed here offers such a platform as part of its ability to survey for Zika, and distinguish it from other arboviruses, based on reagent innovations drawn from the field of “synthetic biology”, including artificially expanded genetic infor- mation systems (AEGIS), self-avoiding molecular recognition systems (SAMRS), biversal nucleotides, transliteration, and evolution-based arbovirus sequence analysis, in a collaboration between the Flor- ida Medical Entomology Laboratory (FMEL), which has live lab-infected mosquitoes with Zika, dengue, and chikungunya, and Firebird, a serial innovator in synthetic biology and diagnostics technology. This R21 project will first add Zika to an already established kit that detects 22 other arboviruses, common and exotic.13 We will benchmark that expanded kit, delivering it to beta testers in FMEL, where multiplexed readout is done using a Luminex instrument. This independent testing guarantees scientific rigor, and will be done by Month 12. In Year 2, we will seek a simpler system, focusing the multiplex on geography-specific target sets, adding biversals to manage sequence evolution of the RNA viruses, replacing Luminex in 10x target assays by a readout based on a 4x4 micro array, and going as far as possible towards a 10x multiplex system that can assay ~ 10 mosquitoes in the field. Towards these ends, we will meet the following specific aims: The outcome of this project will include new Zika science, as well as kits that will allow public health services to enjoy the advantages of these reagent innovations in managing the Zika outbreak, just as those advantages are now enjoyed in many products, including FDA-approved products, for human diagnostics.